Artificial Intelligence in Assistive Technology

By Michael Awood

October 1, 2023

Artificial Intelligence (AI) has been a game-changer in many sectors, including healthcare. AI has been successful in Assistive Technology, an area that’s always been at the forefront of technology.

AI has the potential to revolutionize AT, as highlighted by the UN Special Rapporteur on the rights of persons with disabilities. It can enhance assistive robots, autonomous wheelchairs, and guidance systems for visually impaired individuals. Speech recognition improvements are improving AT applications, while smart homes can boost independence and well-being.

However, challenges exist. AI systems learn from data “training sets,” and if these sets lack diversity, the technology may not reflect the needs of diverse human experiences. Also, the transparency of the data labelling process and lack of diversity in data collection can lead to biased AI tools. Therefore, AI training sets must include AT users to ensure the technology caters to their needs.

Many of these technologies are still in development and have yet to overcome significant barriers. For example, people with dysarthria are hard for speech recognition systems to understand, and smart wheelchairs have trouble detecting descending stairs.

The healthcare workforce should be trained in using digital products and AI tools to educate future generations. This is part of a broader framework to support these technologies’ development and sustainability.

Regulations, standards, and policies also need to keep pace with technological advancements. The proposed EU legislation has raised concerns among the European Disability Forum as it does not sufficiently address and protect the rights of persons with disabilities, especially when AI is used for access to public and private services.

AI could revolutionize AT, but it’s important to involve AT users and healthcare providers in the development process. This involves talking about the ethical use of these technologies and creating rules and policies to govern them.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.